AstraZeneca, a global biopharmaceutical company with ~$43 billion in 2022 revenues and nearly 90,000 employees (aiexpert.network) (blogs.microsoft.com), is rapidly integrating large language model (LLM)–based generative AI—including tools like ChatGPT—across its enterprise and R&D operations. The company has invested heavily (>$250 million) in AI research (emerj.com) (aiexpert.network) and embedded AI in data and processes, from ideating drug targets to streamlining clinical trials (Table below). By mid-2025, AstraZeneca had launched company-wide initiatives to upskill ~12,000 employees on generative AI, with 85–93% of surveyed staff reporting productivity gains from AI tools (www.astrazeneca.com) (www.clinicalresearchnewsonline.com). Notably, AstraZeneca pilots “AI assistants” for tasks like 3D CT-scan analysis and automated protocol drafting, achieving significant time savings for experts (www.clinicalresearchnewsonline.com) (www.clinicalresearchnewsonline.com). These efforts align top-down with AstraZeneca’s 2030 goals (20 new medicines, $80 billion revenue (www.clinicalresearchnewsonline.com) (www.klover.ai)) by accelerating discovery and development processes.
